Healthcare / BiotechnologyNasdaqGM
$7.46
-0.47 (-5.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-55.7M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$362M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-76.3%
↓Gross Margin
N/A
•Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-83.9M · FCF $-79.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $251000.00 | $33.5M | $4.9M |
| Net Income | $-83.9M | $-83.9M | $-58.2M | $-32.8M | $-61.0M |
| EBITDA | $-87.2M | $-87.2M | $-64.9M | $-28.4M | $-58.7M |
| EPS | — | — | -5.81 | -1.41 | -6.51 |
| Operating Margin | — | — | -26805.6% | -91.6% | -1213.3% |
| Net Margin | — | — | -23178.9% | -97.8% | -1236.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.08 | -0.10 | -0.14 |
| Current Ratio | 8.16 | 8.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-79.3M | $-79.3M | $-55.7M | $-50.7M | $-57.1M |
| Returns | |||||
| ROE | -76.3% | -76.3% | -31.2% | 20.2% | 43.3% |
| Valuation | |||||
| P/B | 1.67 | 1.67 | 0.64 | — | — |
| Growth & Yield | |||||
| Revenue Growth | — | — | -99.3% | 579.2% | — |
| EPS Growth | — | — | -312.8% | 78.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+286.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-5.81 → n/d
Residual
+286.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.